Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | hexokinase (hxk) | 0.0418 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0418 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0418 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0418 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.0418 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0262 | 0.3033 | 0.3033 |
Entamoeba histolytica | hexokinase 2 | 0.0418 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0418 | 1 | 1 |
Onchocerca volvulus | 0.0418 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.0418 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.0418 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.0418 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0418 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0418 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0418 | 1 | 0.5 |
Onchocerca volvulus | 0.0418 | 1 | 1 | |
Trypanosoma cruzi | hexokinase, putative | 0.0418 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0418 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0285 | 0.4055 | 0.4055 |
Plasmodium vivax | hexokinase, putative | 0.0418 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0418 | 1 | 1 |
Trypanosoma brucei | hexokinase, putative | 0.0418 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0418 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.0418 | 1 | 0.5 |
Onchocerca volvulus | 0.0418 | 1 | 1 | |
Trypanosoma brucei | hexokinase | 0.0418 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0418 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0418 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0418 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0418 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0418 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Efficacy (functional) | = 70 % | Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT | ChEMBL. | 10956192 |
Efficacy (functional) | = 110 % | Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT | ChEMBL. | 10956192 |
Ki (binding) | < 0.3 nM | In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes | ChEMBL. | 10956192 |
Ki (binding) | = 18.5 nM | In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes | ChEMBL. | 10956192 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.